Identification of an amino acid substitution in human α1 Na, K-ATPase which confers differentially reduced affinity for two related cardiac glycosides

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Ohio 45267-0524.
Journal of Biological Chemistry (Impact Factor: 4.57). 09/1994; 269(39):24120-6.
Source: PubMed


The ouabain-resistant cell line H1C1 displays a 30-fold differential of reduced sensitivity to the structurally related cardiac glycosides digoxin and digitoxin (Baker, R. M. (1976) in Biogenesis and Turnover of Membrane Macromolecules (Cook, J.S., ed) pp. 93-103, Raven Press, New York). Since these ligand congeners differ only by the presence of a hydroxyl group at C-12 of digoxin we predicted that the H1C1 phenotype must reflect a mutation which alters the binding site of the cardiac glycoside receptor (Na,K-ATPase). Complementary DNA encoding the alpha 1 Na,K-ATPase was prepared from H1C1 cell total RNA by reverse transcription-coupled polymerase chain reaction and these cDNAs were cloned. Sequence analysis of the reverse transcriptase-polymerase chain reaction clones revealed several independent isolates containing a G > A transition at nucleotide 332 of the propeptide coding sequence, generating the amino acid substitution C108Y. The ability of this substitution to confer differential sensitivity for digoxin and digitoxin was tested and confirmed by expressing a human alpha 1 C108Y-Na,K-ATPase in wild type HeLa cells and assaying for inhibition of cell growth and inhibition of Na,K-ATPase activity. Phenylalanine or alanine substitutions of this cysteine also confer this pattern of ligand discrimination. Ouabain-resistant Na,K-ATPase substitutions, at positions other than Cys-108 failed to exhibit differential sensitivity indicating that this ligand discrimination is unique to Cys-108 substitutions rather than a general property of cardiac glycoside-resistant mutants. It is proposed that differential resistance of the C108Y receptor for these ligands is a consequence of altering two features of the ligand-receptor interaction; one, a disruption of a common hydrogen bond resulting in general loss of affinity for cardiac glycosides and the other, formation of a new H-bond between the C-12 hydroxyl of digoxin and the receptor, specifically augmenting the stability of this ligand-receptor complex.

  • Source
    • "Construct Resistance Reference -fold HI transmembrane C104F 23 Canessa et al., 1992; Schultheis et al., 1993 Schultheis et al., 1993 Canessa et al., 1992; Askew and Lingrel, 1994 Canessa et al., 1992; Schultheis et al., 1993 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Random mutagenesis with ouabain selection has been used to comprehensively scan the extracellular and transmembrane domains of the alpha1 subunit of the sheep Na+/K+-ATPase for amino acid residues that alter ouabain sensitivity. The four random mutant libraries used in this study include all of the transmembrane and extracellular regions of the molecule as well as 75% of the cytoplasmic domains. Through an extensive number of HeLa cell transfections of these libraries and subsequent ouabain selection, 24 ouabain-resistant clones have been identified. All previously described amino acids that confer ouabain resistance were identified, confirming the completeness of this random mutagenesis screen. The amino acid substitutions that confer the greatest ouabain resistance, such as Gln111-->Arg, Asp121-->Gly, Asp121-->Glu, Asn122-->Asp, and Thr797-->Ala were identified more than once in this study. This extensive survey of the extracellular and transmembrane regions of the Na+/K+-ATPase molecule has identified two new regions of the molecule that affect ouabain sensitivity: the H4 and the H10 transmembrane regions. The new substitutions identified in this study are Leu330-->Gln, Ala331-->Gly, Thr338-->Ala, and Thr338-->Asn in the H4 transmembrane domain and Phe982-->Ser in the H10 transmembrane domain. These substitutions confer modest increases in the concentration of cardiac glycoside needed to produce 50% inhibition of activity (IC50 values), 3.1-7.9-fold difference. The results of this extensive screening of the Na+/K+-ATPase alpha1 subunit to identify amino acids residues that are important in ouabain sensitivity further supports our hypothesis that the H1-H2 and H4-H8 regions represent the major binding sites for the cardiac glycoside class of drugs.
    Preview · Article · Oct 1997 · European Journal of Biochemistry
  • [Show abstract] [Hide abstract]
    ABSTRACT: Based on the knowledge that the digitalis receptor site in Na+/K(+)-ATPase is the interface between two interacting alpha-subunits of the protodimer (alpha beta)2, the present review makes an approach towards modeling the three-dimensional structure of the digitalis intercalating matrix by exploiting the information on: the primary structure and predicted membrane topology of the catalytic alpha-subunit; the determinants of the secondary, tertiary and quaternary structure of the membrane-spanning protein domains; the impact of mutational amino acid substitutions on the affinity of digitalis compounds, and the structural characteristics in potent representatives. The designed model proves its validity by allowing quantitative interpretations of the contributions of distinct amino acid side chains to the special bondings of the three structural elements of digitalis compounds.
    No preview · Article · Feb 1996 · Journal of enzyme inhibition
  • [Show abstract] [Hide abstract]
    ABSTRACT: The need for new inotropic drugs follows from the prevalence of congestive heart failure in the developed countries, and from the fact that the cardiac drugs currently available are clearly inadequate to restore health or even to minimize discomfort and disability (review in [1]). In 1990, Kellermann [2] expected for the coming years that every effort must and will be made to further develop and create new compounds. These should not only beneficially affect the hemodynamic and functional impairment of patients with congestive heart failure, but also hopefully contribute to reaching an achievable goal, namely, the prevention of the clinical manifestations of heart failure. The arduous research, on the part of the pharmaceutical industry, to find a nonsteroidal “digitalis replacement” cannot be regarded as having been accomplished [3].The present review deliberately excludes the great number of cardioactive compounds of nonsteroidal types and divergent points of attack because they do not appear to promise progress in the treatment of cardiac failure (review in [4,5]). Taking the above demand as our challenge, we review in this chapter where we presently are in the search for ideal inotropic steroids. Earlier stages of this endeavor, documented elsewhere [6–8], will but cursorily be cited here. Our more recent approach has been derived from the hypothesis that the earlier failures in the synthetic further development of inotropic steroids with improved therapeutic range were based on the use of C/D-cis connected steroids as lead compounds which form the core in the medicinally used cardiac glycosides.
    No preview · Article · Feb 1996 · Fortschritte der Arzneimittelforschung. Progress in drug research. Progrès des recherches pharmaceutiques
Show more